Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs
Emilio Portaccio(University of Florence), Paolo Immovilli(University of Florence), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Angelo Ghezzi, E. Piscolla(Vita-Salute San Raffaele University), Lucia Moiola(Vita-Salute San Raffaele University), Alessandra Protti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Roberto Bergamaschi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Marta Radaelli(Humboldt-Universität zu Berlin), Franco Granella(University of Parma), Vittorio Martinelli(Vita-Salute San Raffaele University), Maria Giovanna Marrosu(University of Cagliari), María Trojano(University of Bari Aldo Moro), Lorenzo Razzolini(University of Florence), Bahia Hakiki, Alessandra Lugaresi(Istituto delle Scienze Neurologiche di Bologna), Gıancarlo Comı(Casa di Cura Columbus), Maria Pia Amato(University of Florence), Giovanna De Luca(University of Udine), Rocco Totaro(San Salvatore Hospital), Elisabetta Capello(Ospedale Policlinico San Martino), Andrea Sturchio(University of Insubria), R. Marazzi, Damiano Paolicelli(University of Bari Aldo Moro), Luisa Pastò(University of Florence), Laura De Giglio(Vita-Salute San Raffaele University), Paola Cavalla, Luisa Caniatti(University of Catania), Marta Giannini(Vita-Salute San Raffaele University), Francesco Patti(University of Catania), Carlo Pozzilli(Sapienza University of Rome), Gianluigi Mancardi(Istituti Clinici Scientifici Maugeri), Claudio Solaro(Rina Services (Italy)), G. Siracusa, A. Rizzo(University of Florence), C. Spreafico(University of Florence), M. R. Tola(Vita-Salute San Raffaele University), Silvia Masera(University of Florence)
Cited by 84
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k